Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Is stem cell transplantation still needed for adult Philadelphia chromosome-positive acute lymphoblastic leukemia receiving tyrosine kinase inhibitors therapy?: A systematic review and meta-analysis

“…For TKI treatment, imatinib was the most commonly used in 22 studies, with a dose range of 400-800 mg/day [9-13, 15, 17, 22, 23, 25, 27-38]. Dasatinib is used in nine studies, with a dose range of 70-140 mg/day [10,12,16,24,29,[35][36][37][38], ponatinib PLOS ONE is used in two studies, with a dose range of 15-45 mg/day [26,36], and nilotinib is used in two studies, with a dose range of 600-800 mg/day [35,38]. Regarding post-transplant TKI, it is given to all patients in nine studies [9,12,16,25,27,30,33,37], to some patients in six studies [13-15, 26, 36, 38], to none of the patients in one study [31], and no report of post-transplant TKI in ten studies [10,11,17,23,24,28,29,32,34,35].…”

“…For the outcomes of allo-HSCT and auto-HSCT groups, a total of nine and eight studies reported OS rates (as 2-year rate by one study [14], 3-year rate by three studies [25,35,38], 4-year rate by two studies [9,15] and 5-year rate by three studies [13,17,22]) and DFS (as 2-year rate by one study [14], 3-year rate by two studies [35,38], 4-year rate by two studies [9,15] and 5-year rate by three studies [13,17,22]), respectively. Four and six studies reported TRM rates (specified as 100-day rate by two studies [22,25], 4-year rate by one study [15] and one study without specified duration [35]) and CIR rates (2-year rate by one study [14], 3-year…”

“…rate by one study [38], 4-year rate by one study [15], 5-year rate by two studies [13,22] and one study without specified duration [35]), respectively. The pooled meta-analysis found that Ph + ALL patients who received allo-HSCT had comparable OS and DFS to those who received auto-HSCT with pooled OR of 1.04 (95% CI, 0.74-1.44; I 2 = 0%) and 1.09 (95% CI, 0.79-1.49; I 2 = 0%), respectively (Fig 3A and 3B).…”

“…For the outcomes of auto-HSCT and CMT groups, a total of three studies reported OR and DFS rates (as 4-year rate by two studies [9,15], and 5-year rate by one study [17]). The pooled meta-analysis showed that Ph + ALL patients who received auto-HSCT had significantly sustained OS and DFS compared to those who received only CMT with pooled odds ratio (OR) of 7.04 (95% CI, 1.97-25.15; I 2 = 0%) and 5.78 (95% CI, 1.04-32.19; I 2 = 42%), respectively [9,13,15,17,22,25,35,38] and pooled OR of DFS 1.00; 95% CI, 0.67-1.50; I 2 = 0% [9,13,15,17,22,35,38]) (S2C and S2D Fig).…”

Optimizing Autologous Hematopoietic Stem Cell Transplantation for Acute Leukemia

“…F I G U R E 3 Prognosis of Philadelphia-positive (Ph + ) acute lymphocytic leukemia (ALL) patients after auto-and matched sibling donor (MSD)-SCT. 30 A, The overall survival (OS); B, disease-free survival (DFS); C, relapse; D, transplant-related mortality (TRM), in auto group (n = 31, solid line) and allo group (n = 47, broken line) COLLECTION At IH, most stem cells are harvested from peripheral blood after intensive chemotherapy followed by granulocyte-colony stimulating factor (G-CSF). 29 G-CSF is given at a dose of 10 μg/kg per day for 7 to 10 days after chemotherapy.…”